share_log

Cardio Diagnostics | 4: Statement of changes in beneficial ownership of securities-Officer Dogan Meeshanthini

Cardio Diagnostics | 4:持股变动声明-高管 Dogan Meeshanthini

SEC announcement ·  02/22 03:56
牛牛AI助手已提取核心信息
Cardio Diagnostics Holdings, Inc. (CDIO.US) has reported a transaction by Chief Executive Officer Dogan Meeshanthini on January 23, 2024. The details of the transaction, including the number of shares involved and the transaction price, have not been disclosed in the announcement. The action type and status, as well as the number of shares held by Meeshanthini after the transaction, remain unspecified. Investors are advised to monitor further disclosures for complete transaction details.
Cardio Diagnostics Holdings, Inc. (CDIO.US) has reported a transaction by Chief Executive Officer Dogan Meeshanthini on January 23, 2024. The details of the transaction, including the number of shares involved and the transaction price, have not been disclosed in the announcement. The action type and status, as well as the number of shares held by Meeshanthini after the transaction, remain unspecified. Investors are advised to monitor further disclosures for complete transaction details.
Cardio Diagnostics Holdings, Inc.(CDIO.US)于2024年1月23日报告了首席执行官多根·梅尚蒂尼的一笔交易。该交易的细节,包括所涉及的股票数量和交易价格,尚未在公告中披露。交易类型和状态以及Meeshanthini在交易后持有的股票数量仍未具体说明。建议投资者监督进一步的披露,以了解完整的交易细节。
Cardio Diagnostics Holdings, Inc.(CDIO.US)于2024年1月23日报告了首席执行官多根·梅尚蒂尼的一笔交易。该交易的细节,包括所涉及的股票数量和交易价格,尚未在公告中披露。交易类型和状态以及Meeshanthini在交易后持有的股票数量仍未具体说明。建议投资者监督进一步的披露,以了解完整的交易细节。

译文内容由第三方软件翻译。


牛牛AI助手部分由第三方人工智能模型基于资讯内容自动生成,只对中国内地以外的地区提供。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。